Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...
Alcon and RxSight, Inc have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting ...
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies ...
ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.
Clareon Vivity is the first and only non-diffractive extended depth of focus (EDOF) IOL with the wavefront-shaping X-WAVE Technology on Alcon’s most advanced lens platform1-6 Clareon Vivity joins ...
Alcon is the leading manufacturer of intraocular lenses. Of the 20 million cataract procedures conducted globally each year, only 4% of patients receive PC-IOLs. Now, with a lens that offers a visual ...
MarketBeat on MSN
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook
Key Points Interested in RxSight, Inc.? Here are five stocks we like better. RxSight's preliminary Q2 sales fell 20% year ...
Aziz Mottiwala becomes RxSight CEO July 20 amid commercial challenges. The move follows the $200M Alcon deal for adjustable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results